A new study proposes a modelling strategy to identify reactions, genes and metabolites relevant in hepatocellular carcinoma using in silico and in vivo analyses. The proposed genome-scale metabolic model integrates genomic and proteomic information, and points to statins, among others, as potential chemopreventive and anticancer drugs.
References
European Association for the Study of the Liver & European Organisation for Research and Treatment of Cancer. EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56, 908–943 (2012).
Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).
Agren, R. et al. Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling. Mol. Syst. Biol. 10, 721 (2014).
Notarnicola, M., Tutino, V. & Caruso, M. G. Tumor-induced alterations in lipid metabolism. Curr. Med. Chem. http://dx.doi.org/10.2174/0929867321666140303122426.
Singh, S., Singh, P. P., Roberts, L. R. & Sanchez, W. Chemopreventive strategies in hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 11, 45–54 (2014).
Singh, S., Singh, P. P., Singh, A. G., Murad, M. H. & Sanchez, W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 144, 323–332 (2013).
Tsan, Y. T. et al. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J. Clin. Oncol. 31, 1514–1521 (2013).
Van der Heiden, M. G. Targeting cancer metabolism: a therapeutic window opens. Nat. Rev. Drug Discov. 10, 671–684 (2011).
Hoshida, Y. et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 69, 7385–7392 (2009).
Mardinoglu, A. et al. Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease. Nat. Commun. 5, 3083 (2014).
Acknowledgements
J.M.L. is supported by grants from the European Commission Framework Programme 7 (Heptromic, proposal number 259744), the US National Institute of Diabetes and Digestive and Kidney Diseases (1R01DK076986), the Samuel Waxman Cancer Research Foundation, the Spanish National Health Institute (SAF-2010-16055) and the Asociación Española para el Estudio del Cáncer.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Pinyol, R., Llovet, J. Genome-scale metabolic models for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 11, 336–337 (2014). https://doi.org/10.1038/nrgastro.2014.70
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2014.70
- Springer Nature Limited